MAIA Biotechnology, Inc. (NYSE American: MAIA) is proud to announce that the first two patients have been successfully dosed in Europe in its Phase 2 clinical trial, THIO-101. This trial is designed to evaluate the efficacy of THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). After gaining regulatory clearances from Hungary, Poland, and Bulgaria, five clinical sites have now been established in these countries.
In July 2022, the first patient was dosed in the THIO-101 trial, a groundbreaking clinical trial of THIO, a first-in-class cancer telomere targeting agent, in patients with advanced NSCLC who have either progressed or relapsed through the initial treatments with an immune checkpoint inhibitor alone, or in combination with chemotherapy. Following the successful commencement of the trial in Australia, dosing of patients in Europe began in March 2023. The primary objectives of the THIO-101 trial are to evaluate the safety and tolerability, as well as preliminary clinical efficacy, of THIO in this patient population.
MAIA Pharmaceuticals is thrilled to announce the commencement of patient enrollment in Europe for its groundbreaking experimental therapy, THIO-101. Five sites have been activated in three countries, with the potential to revolutionize treatment for Non-Small Cell Lung Cancer, a condition with limited treatment options and a high mortality rate. MAIA’s Chairman and Chief Executive Officer, Vlad Vitoc, M.D., expressed his satisfaction with the progress that has been made thus far, as THIO-101 is now being evaluated in clinical trials in Australia and three European countries.
Mihail Obrocea, MD – Chief Medical Officer at MAIA – is thrilled with the initiation of dosing in their Phase 2 clinical trial of THIO-101 in Europe. This marks an important milestone in the journey of MAIA towards understanding the pharmacokinetics and safety of the first-in-class investigational medicine. We are eagerly anticipating the results of the trial, which we hope to share later this year.
About THIO-101, a Phase 2 Clinical Trial
THIO-101 is a groundbreaking, open-label clinical trial that is set to evaluate the potential of THIO to activate the immune system in non-small cell lung cancer (NSCLC) patients. The trial will test the hypothesis that pre-administration of low doses of THIO in combination with an immune checkpoint inhibitor will improve and prolong immune response in patients who previously did not respond or developed resistance to earlier checkpoint inhibitor treatments. The primary objectives of the study are to assess the safety and tolerability of THIO and to measure its efficacy through overall response rate (ORR) as the primary clinical endpoint. With the potential to revolutionize the treatment of NSCLC, THIO-101 is an exciting new opportunity to explore the power of the immune system.
THIO, an investigational telomere-targeting agent currently in clinical development, is a revolutionary agent being studied to evaluate its effectiveness in the treatment of Non-Small Cell Lung Cancer (NSCLC). Telomeres and telomerase, essential components of cancer cell survival and resistance to therapies, are targeted by THIO in an effort to provide cancer patients with an advanced treatment option beyond the standard-of-care regimens of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is an innovative immuno-oncology company striving to make a difference in the lives of those affected by cancer. We are developing THIO, a groundbreaking and potentially first-in-class telomere targeting agent that could be the answer to treating telomerase-positive cancers. We are passionate about providing the best possible care for those fighting cancer and are dedicated to making meaningful improvements in their lives.